Global Radiotherapy-Induced Nausea and Vomiting Treatment Market By Drug Type: (Serotonin (5-HT3) receptor antagonist, Neurokinin-1 (NK1) receptor antagonist, Corticosteroids) By Route of Administration: (Oral, Parenteral) By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Radiotherapy-Induced Nausea and Vomiting Treatment Market Overview:

The global Radiotherapy-Induced Nausea and Vomiting Treatment Market is projected to reach a valuation of USD 5,329.25 Mn by 2032 at a CAGR of 7.20%, from USD 2,659.00 Mn in 2022.

Nausea and vomiting are side effects caused by cancer treatment and affect most patients who undergo chemotherapy. Radiation therapy to the brain, gastrointestinal tract, or liver also causes nausea and vomiting. Nausea and vomiting caused by Radiotherapy (RT) are not that severe as compared to those caused by chemotherapy, where nausea and vomiting can last for several days in certain cases. These side effects are clinically important and can be painful for patients. Depending on the site of irradiation, more than 40% of patients that undergo radiotherapy will experience nausea and vomiting.

Fractionated radiotherapy treatment may comprise up to 40 fractions over a 6 to 8-week period, and prolonged symptoms of nausea and vomiting affect life quality. Furthermore, intractable nausea and vomiting may result in patients refusing or delaying further radiotherapy treatment. The prevalence and severity of nausea and vomiting depend on RT-related factors including irradiated site, total dose, irradiated volume, etc., and patient-related factors such as gender, age and health condition, recent chemotherapy treatments, etc. Published observational trials on Radiotherapy-Induced Nausea and Vomiting (RINV) highlight that the cumulative incidence of vomiting and nausea is for 1/3rd of the patients undergoing radiotherapy.

As per the document presented by the Multinational Association of Supportive Care in Cancer (MASCC) and the European Society of Clinical Oncology (ESMO), various patients in Europe are unable to receive adequate treatment for Chemotherapy-Induced Nausea and Vomiting (CINV) due to excessive regulatory restrictions on the availability as well as the accessibility of drugs.

Detail Segmentation:

The global radiotherapy-induced nausea and vomiting treatment market is segmented on the basis of – Drug Type, Route Of Administration, Distribution Channel, and Region. This market’s segmentation is listed below:

By Drug Type

• Serotonin (5-HT3) receptor antagonist
• Neurokinin-1 (NK1) receptor antagonist
• Corticosteroids
• Dopamine antagonists

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• e-Commerce Platforms

By Region

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Market Dynamics:

The increasing occurrence of different types of cancers globally, strong research & development in oncology treatment will help in boosting the development of Radiotherapy-Induced Nausea and Vomiting Treatment. According to data presented by the Global Cancer Observatory (GCO) in 2020, around 19.3 Mn new cases of cancer were diagnosed, with there being approx. 10 Mn cancer deaths globally occurred. By 2040, this figure is expected to grow to more than 27.5 Mn new cancer cases and cancer deaths will be more than 16 Mn.

In addition, favorable government initiatives and a surge in the number of research & development activities are some of the factors anticipated to increase the market growth. A recent trend observed in this target market is that major players are now focusing on funding research & development activities to produce more advanced products. Major industry players are involved in long-term contracts with medical care organizations as well as being engaged in partnerships/strategic alliances with other players to extend their respective business presence.

Key Players:

Some of the major manufacturers and suppliers of the global radiotherapy-induced nausea and vomiting treatment market include:

• Acacia Pharma Gr
• Baxter International Inc.
• Lee’s Pharmaceutical Holdings
• Mundipharma International Limited
• Kyowa Hakko Kirin Co. Ltd.
• GlaxoSmithKline plc
• Merck & Co. Inc.
• Teva Pharmaceutical Industries Ltd.
• Heron Therapeutics Inc.
• F. Hoffmann-La Roche AG
• Tesaro Inc.
• Others

For the Radiotherapy-Induced Nausea and Vomiting Treatment Market research study, the following years have been considered to estimate the market size: